Скачать или смотреть Replimune Stock Skyrockets 82% After FDA Accepts Melanoma Drug Resubmission | RP1 Approval Update

Replimune ($REPL) shares soared 82% in premarket trading after the FDA accepted its resubmission for RP1, a biologics license application targeting advanced melanoma. This marks a major turnaround after the agency previously rejected the drug due to trial inadequacies.

📅 The FDA now considers the resubmission a complete response and will decide on RP1’s approval by April 10, 2026.

🔍 In this video, we break down:
What triggered the massive stock surge
The FDA’s updated stance on RP1
Replimune’s path to potential approval
Implications for biotech investors and melanoma treatment

📊 Despite being down 63% YTD, Replimune’s rebound could signal renewed investor confidence. Is this the beginning of a biotech comeback?

👉 Subscribe for more updates on FDA approvals, stock market movers, and biotech breakthroughs.

Replimune #FDAApproval #BiotechStocks #RP1 #MelanomaTreatment #StockMarketNews
#marketupdate ##stockmarket #shorts